Treatment of Cognitive Deficits in Genetic Disorders: A Systematic Review of Clinical Trials of Diet and Drug Treatments.

IMPORTANCE Knowing the underlying etiology of intellectual disability in genetic disorders holds great promise for developing targeted treatments. Although successful preclinical studies and many positive clinical studies have been reported, it is unclear how many purported therapies have become established treatments. The quality of the clinical trials may be an important determinant for achieving clinical impact. OBJECTIVE To evaluate clinical impact, strengths, and weaknesses of clinical trials of diet or drug treatments to improve cognitive function in patients with a genetic disorder. EVIDENCE REVIEW MEDLINE, EMBASE, PsycINFO, and Cochrane databases were searched from inception date to January 26, 2014, for clinical trials with cognitive outcomes in patients with genetic disorders. Outcome measures of randomized clinical trials (RCTs) were compared between trial registries and reports, and trials were evaluated for the quality of design using the Jadad score and Consolidated Standards of Reporting Trials (CONSORT) criteria. FINDINGS We identified 169 trial reports of 80 treatments for 32 genetic disorders. Seventy-five trials (44.4%) reported potential efficacy, of which only 2 therapies are now established treatments, namely, dietary restriction for phenylketonuria and miglustat for Niemann-Pick disease type C. The median sample size for RCTs was 25 (range, 2-537). Only 30 of 107 RCTs (28.0%) had acceptable Jadad scores exceeding 3. Reporting of key CONSORT items was poor. Reported outcome measures matched preregistered outcome measures in trial registries in only 5 of 107 RCTs (4.7%). CONCLUSIONS AND RELEVANCE The number of trials in the field of cognitive genetic disorders is rapidly growing, but clinical impact has been limited because few drugs have become established treatments and the benefit of most drugs remains unclear. Most trials have small sample sizes and low quality of design. Predefinition of outcome measures, improved trial reporting and design, and international collaboration to increase recruitment are needed to unequivocally determine efficacy of drugs identified in preclinical research.

[1]  C. Walsh,et al.  New innovations: Therapeutic opportunities for intellectual disabilities , 2013, Annals of neurology.

[2]  J. Ioannidis,et al.  Evaluation of Excess Significance Bias in Animal Studies of Neurological Diseases , 2013, PLoS biology.

[3]  Brian A. Nosek,et al.  Power failure: why small sample size undermines the reliability of neuroscience , 2013, Nature Reviews Neuroscience.

[4]  R. Ophoff,et al.  Genetic causes of developmental disorders. , 2013, Current opinion in neurology.

[5]  B. V. van Bon,et al.  Diagnostic exome sequencing in persons with severe intellectual disability. , 2012, The New England journal of medicine.

[6]  L. Maffei,et al.  Treatment of Neurodevelopmental Disorders in Adulthood , 2012, The Journal of Neuroscience.

[7]  M. Bear,et al.  Effects of STX209 (Arbaclofen) on Neurobehavioral Function in Children and Adults with Fragile X Syndrome: A Randomized, Controlled, Phase 2 Trial , 2012, Science Translational Medicine.

[8]  J. Ioannidis.  Extrapolating from Animals to Humans , 2012, Science Translational Medicine.

[9]  T. Johnson,et al.  Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial , 2012, The Lancet.

[10]  R. Barker,et al.  Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial , 2011, The Lancet Neurology.

[11]  M. Tejada,et al.  Folic acid for fragile X syndrome. , 2011, The Cochrane database of systematic reviews.

[12]  K. Kieburtz,et al.  Advocacy Recruiting for Huntington’s Disease Clinical Trials , 2011, PLoS currents.

[13]  D. Moher,et al.  CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010, Trials.

[14]  D. Howells,et al.  Can Animal Models of Disease Reliably Inform Human Studies? , 2010, PLoS medicine.

[15]  V. Poustie,et al.  Dietary interventions for phenylketonuria. , 2010, The Cochrane database of systematic reviews.

[16]  C. Sampaio,et al.  Therapeutic interventions for disease progression in Huntington's disease. , 2009, The Cochrane database of systematic reviews.

[17]  Cristina Sampaio,et al.  Therapeutic interventions for symptomatic treatment in Huntington's disease. , 2009, The Cochrane database of systematic reviews.

[18]  Alcino J. Silva,et al.  Effect of Simvastatin on Cognitive Functioning in Children with Neurofibromatosis Type 1 a Randomized Controlled Trial , 2022 .

[19]  Tasha R. Stanton,et al.  Scales to Assess the Quality of Randomized Controlled Trials: A Systematic Review , 2008, Physical Therapy.

[20]  M. Patterson,et al.  Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study , 2007, The Lancet Neurology.

[21]  R. Horton,et al.  Clinical trial registration: looking back and moving ahead. , 2007, The Medical journal of Australia.

[22]  P. Sandercock,et al.  Comparison of treatment effects between animal experiments and clinical trials: systematic review , 2006, BMJ : British Medical Journal.

[23]  Douglas G Altman,et al.  Epidemiology and reporting of randomised trials published in PubMed journals , 2005, The Lancet.

[24]  D. Altman,et al.  Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors , 2005, BMJ : British Medical Journal.

[25]  P. Sandercock,et al.  Where is the evidence that animal research benefits humans? , 2004, BMJ : British Medical Journal.

[26]  V. Prasher,et al.  A 24‐week, double‐blind, placebo‐controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease—pilot study , 2002, International journal of geriatric psychiatry.

[27]  L. Kluwe,et al.  Treatment of ADHD in neurofibromatosis type 1 , 2002, Developmental medicine and child neurology.

[28]  S. Walkley,et al.  Critical role for glycosphingolipids in Niemann-Pick disease type C , 2001, Current Biology.

[29]  Douglas G Altman,et al.  Systematic reviews in health care: Assessing the quality of controlled clinical trials. , 2001, BMJ.

[30]  D. Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials , 2001, Annals of Internal Medicine.

[31]  Douglas G. Altman,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials , 2001, The Lancet.

[32]  Nel Roeleveld,et al.  The prevalence of mental retardation: a critical review of recent literature , 1997, Developmental medicine and child neurology.

[33]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[34]  D. Altman.  Statistics and ethics in medical research: III How large a sample? , 1980, British medical journal.